Methylene blue and ADHD: study inventory

Search checked September 12, 2026. This inventory separates background experiments, an irrelevant keyword match, and evidence gaps. No ADHD treatment trial was located. A gap row is not a study.

Search population, outcome, author, or gap

5 of 5 records shown.

On smaller screens, scroll the table horizontally to read findings and evidence gaps.

Population, design, findings, and explicit limits
Record and classification	Population and design	Intervention and findings	ADHD evidence gap
Rodriguez et al., 2016Background experiment PMID 27351678	26 healthy adults analyzed, ages 22–62. Randomized, double-blind, placebo-controlled. Psychiatric disorders and recent psychiatric medication excluded.	Single oral USP-grade methylene blue administration versus blue-colored placebo. Attention, short-term memory and functional MRI before and about 1 hour afterward. Attention behavior interaction P=.43; memory interaction P=.09. Both nonsignificant. Imaging changes reported.	No diagnosed ADHD cohort or symptom endpoint. A within-group memory increase does not establish superiority over placebo. No repeated-use or medication-combination answer.
Telch et al., 2014Background experiment PMID 25018057	42 adults with marked claustrophobic fear. Randomized, double-blind study after exposure training; 23 received methylene blue, 19 placebo.	Post-session methylene blue versus placebo. Contextual memory at 1 and 30 days; fear retesting at 1 month. Fear effects depended on successful fear reduction during training. Contextual memory enhancement reported.	No ADHD symptom outcome. A fear-learning intervention cannot establish everyday attention, impulsivity, or hyperactivity benefit.
Methemoglobinemia case, 2016Excluded keyword match PMID 27099330	One adult with a complex medical history that included ADHD. Case report of apparent rasburicase-induced methemoglobinemia.	Methylene blue was avoided because of suspected G6PD deficiency, subsequently confirmed. Ascorbic acid was used. This is not a methylene blue treatment study.	Mentioning ADHD in medical history does not constitute an ADHD trial or a positive treatment result.
Diagnosed ADHD efficacyEvidence gap, not a study	Targeted PubMed and ClinicalTrials.gov searches did not locate a methylene blue intervention trial in participants recruited with diagnosed ADHD.	PubMed returned the case report above; ClinicalTrials.gov returned zero matching records for the documented query.	No located controlled estimate for core symptoms, everyday functioning, comparison with established medication, or pediatric efficacy. No ADHD dose established by these records.
Repeated use and medication combinationsEvidence gap, not a study	No relevant controlled combination trial located in the reviewed records.	Short experiments outside ADHD do not assess chronic coadministration with ADHD medicines. Medicine labels contain MAO inhibitor contraindications.	No established additional benefit or safe combination regimen. Do not infer safety from a healthy-volunteer experiment that excluded psychiatric medications.